In addition to SCLC-P cells, this study reveals that mSWI/SNF ATPase degraders have potent therapeutic activity against a subset of MM and DLBCL cells that are dependent on the POU2AF1 coactivator. Here, POU2AF1 is linked to diffuse large B-cell lymphoma.